New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
04:55 EDTALKS, ALKS, ANGO, ANGO, SNSS, SNSS, VHS, VHS, IART, IART, OCR, OCR, BKD, BKD, BAX, BAX, ARIA, ARIARBC Capital to host a conference
Healthcare Conference is being held in New York on February 26-27.
News For ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA From The Last 14 Days
Check below for free stories on ALKS;ANGO;SNSS;VHS;IART;OCR;BKD;BAX;ARIA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 10, 2014
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
April 9, 2014
19:01 EDTANGOOn The Fly: After Hours Movers
Subscribe for More Information
16:09 EDTANGOAngioDynamics sees Q4 adjusted EPS 18c-21c, consensus 14c
Sees Q4 revenue $91M-$95M, consensus $93.17M.
16:09 EDTANGOAngioDynamics trades up after results, first look
Subscribe for More Information
16:08 EDTANGOAngioDynamics sees FY14 adjusted EPS 60c-63c had seen 63c-67c
Subscribe for More Information
16:06 EDTANGOAngioDynamics reports Q3 adjusted EPS 16c, consensus 9c
Reports Q3 revenue $88.2M, consensus $88.85M.
15:19 EDTANGONotable companies reporting after market close
Subscribe for More Information
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
April 8, 2014
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
13:30 EDTSNSSSunesis vosaroxin shown to be effective, says Wedbush
Wedbush believes that initial data from a Phase Ib/II study indicates that Sunesis' vosaroxin and decitabine are more effective in treating acute myeloid leukemia and myelodysplastic syndrome than decitabine alone. The firm notes that vosaroxin combined with decitabine appeared to be safe. It reiterates a $10 price target and Outperform rating on Sunesis.
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
08:11 EDTSNSSSunesis announces presentation of positive results from Vosaroxin trial
Subscribe for More Information
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:22 EDTBAXCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
April 7, 2014
10:07 EDTARIAARIAD has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Harvey Berger on April 10 at 10 am.
07:27 EDTSNSSAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
April 4, 2014
08:36 EDTIARTIntegra LifeSciences receives FDA clearance for use of Camino catheter with MRI
Subscribe for More Information
April 3, 2014
07:01 EDTBAXKamada announces U.S. proof-of-concept study with Glassia
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use